Drug Discovery. Accelerated.
IMPROVING HEALTH THROUGH COMPUTATION
twoXAR is an artificial intelligence-driven drug discovery company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships.
Fast: typical engagement is from handshake to predictions in less than six months
Scalable: process data sets of any size in minutes using an elastic computing environment
Unbiased: predictions are based on statistical modeling – you control the amount of human input
Comprehensive: works with gene expression, protein-interaction, chemical structure, MOA, and clinical data, among others – it even handles noisy or incomplete assays
Agnostic: models work with any disease and have been tested on more than 20 diseases to date
User-friendly: predictions are summarized in easy-to-read PDF reports
No capex: service model requires no software license fees or local hardware installations
Want to learn more about DUMA™ and how it worked in disease-specific case studies? Connect.
twoXAR's founders share more than a name, they share a commitment to disrupting the drug discovery process and accelerating the development of new medicines for rare and common health conditions. They are supported by a team of experts in data science and systems biology and a network of advisers that includes biopharmaceutical industry and clinical research veterans.
Andrew A. Radin
CEO & Co-Founder
Prior to co-founding twoXAR, Andrew held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew developed the company's proprietary algorithm and as Chief Executive Officer is focused on overall company strategy, product development and fundraising.
Andrew studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in computer science from Rochester Institute of Technology.
Andrew M. Radin
CBO & Co-Founder
Andrew M. Radin formerly worked as an investor in venture and private equity funds and has designed, built, and managed several small organizations. Andrew co-founded a mobile platform startup while at MIT. As Chief Business Officer of twoXAR, Andrew is focused on validating the market, identifying customers, building the team, and fundraising.
Andrew holds a Master in Business Administration degree from MIT Sloan, a Bachelor of Science degree in biochemistry and cell biology from UCSD, and a Bachelor of Arts degree in economics from UCSD.
Yen S Low, Aaron C Daugherty, Elizabeth A Schroeder, William Chen, Tina Seto, Susan Weber, Michael Lim, Trevor Hastie, MayaMathur, Manisha Desai, Carl Farrington, Andrew A Radin, Marina Sirota, Pragati Kenkare, Caroline A Thompson, Peter P Yu, Scarlett LGomez, George W Sledge Jr, Allison W Kurian, Nigam H Shah. Journal of the American Medical Informatics Association. EPub: December 9, 2016
by: Andrew A. Radin
Today we announced our collaboration with Santen, a world leader in the development of innovative ophthalmology treatments. Scientists at twoXAR will use our proprietary computational drug discovery platform to discover, screen and prioritize novel drug candidates with potential application in glaucoma. Santen will then develop and commercialize drug candidates arising from the collaboration. This collaboration is an exciting example of how artificial intelligence-driven approaches can move beyond supporting existing hypotheses and lead the discovery of new drugs. Combining twoXAR’s unique capabilities with Santen’s experience in ophthalmic product development and commercialization… read post here.
by: Carl Farrington
Software Architect, twoXAR
We at twoXAR were very honored to be included this week in The AI 100, CBInsight’s list of top private Artificial Intelligence companies. It’s given me a chance to reflect on how we employ AI relative to others in the industry.
Our focus is on drug development — and being one of the few biopharma companies to be included in the list, we use AI in a unique way. Where others may be using AI as the sole ingredient... read post here.